Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells

Breast Cancer Research and Treatment

Volumn 143, Issue 2, 2014, Pages 301-312

  Goard, Carolyn A ^a,b   Chan Seng Yue, Michelle ^a,c   Mullen, Peter J ^a   Quiroga, Ariel D ^d   Wasylishen, Amanda R ^a,b   Clendening, James W ^a,b   Sendorek, Dorota H S ^c   Haider, Syed ^c   Lehner, Richard ^d   Boutros, Paul C ^b,c   Penn, Linda Z ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Breast cancer; Drug sensitivity; Estrogen receptor; Fluvastatin; Gene expression; Statin

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FLUINDOSTATIN; HYDROXYTAMOXIFEN; LIPID; MESSENGER RNA; MEVALONIC ACID; ANTINEOPLASTIC AGENT; ANTIOXIDANT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; MYC PROTEIN; MYC PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CELL ASSAY; CELL DEATH; CELL METABOLISM; CHEMOSENSITIVITY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC DATABASE; HOMEOSTASIS; HUMAN; HUMAN CELL; MOLECULAR GENETICS; ONCOGENE MYC; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; APOPTOSIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; MCF 7 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYMETHYLGLUTARYL-COA-REDUCTASES, NADP-DEPENDENT; INDOLES; MCF-7 CELLS; MEVALONIC ACID; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84893645204     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2800-y     Document Type: Article

References (39)

1. Kaufmann M, Pusztai L (2011) Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel. Cancer 117:1575-1582. doi: 10.1002/cncr.25660
2. Szekely B, Pusztai L (2011) The value of genomic analysis of breast cancer in drug development. J Natl Cancer Inst Monogr 2011:60-62. doi: 10.1093/jncimonographs/lgr039
3. Mandrekar SJ, Sargent DJ (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034. doi: 10.1200/JCO.2009.22.3701
4. Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, Lieftucht A, Mazumder A, Milloy J, Shaw PM, Swank D, Wang J, Berndt ER, Goodsaid F, Palmer MC (2011) Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 10:817-833. doi: 10.1038/nrd3557
5. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517-526
6. Clendening JW, Penn LZ (2012) Targeting tumor cell metabolism with statins. Oncogene 31:4967-4978. doi: 10.1038/onc.2012.6
7. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M (2012) Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64:102-146. doi: 10.1124/pr.111.004994
8. Endo A, Tsujita Y, Kuroda M, Tanzawa K (1977) Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 77:31-36
9. Brown MS, Goldstein JL (1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21:505-517
10. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430. doi: 10.1038/343425a0
11. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ (2010) Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 119:137-144. doi: 10.1007/s10549-009-0507-x
12. Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, Uhlen M, Johannesson H, Rose C, Grabau D, Borgquist S (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138:499-508. doi: 10.1007/s10549-013-2473-6
13. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC (2006) Breast cancer growth prevention by statins. Cancer Res 66:8707-8714
14. Mueck AO, Seeger H, Wallwiener D (2003) Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 10:332-336. doi: 10.1097/01.GME.0000055485.06076. 00
15. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Borresen-Dale AL, Levine AJ, Bargonetti J, Prives C (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244-258. doi: 10.1016/j.cell.2011.12.017
16. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527
17. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Caldas C, Aparicio S, Brenton JD, Ellis I, Huntsman D, Pinder S, Purushotham A, Murphy L, Bardwell H, Ding Z, Jones L, Liu B, Papatheodorou I, Sammut SJ, Wishart G, Chia S, Gelmon K, Speers C, Watson P, Blamey R, Green A, Macmillan D, Rakha E, Gillett C, Grigoriadis A, di Rinaldis E, Tutt A, Parisien M, Troup S, Chan D, Fielding C, Maia AT, McGuire S, Osborne M, Sayalero SM, Spiteri I, Hadfield J, Bell L, Chow K, Gale N, Kovalik M, Ng Y, Prentice L, Tavare S, Markowetz F, Langerod A, Provenzano E, Borresen-Dale AL (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. doi: 10.1038/nature10983
18. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747-752. doi: 10.1038/35021093
19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874. doi: 10.1073/pnas.191367098
20. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393-10398. doi: 10.1073/pnas.1732912100
21. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93:1308-1318
22. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30:256-268
23. Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, Sharom FJ, Penn LZ (2010) Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer 127:2936-2948. doi: 10.1002/ijc.25295
24. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 107:15051-15056. doi: 10.1073/pnas.0910258107
25. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607. doi: 10.1038/nature11003
26. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575. doi: 10.1038/nature11005
27. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 109:2724-2729. doi: 10.1073/pnas.1018854108
28. Mason RP, Walter MF, Day CA, Jacob RF (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96:11F-23F. doi: 10.1016/j.amjcard.2005.06.008
29. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ (2006) Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57:155-164
30. Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, Jurisica I, Trudel S, Penn LZ (2010) Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood 115:4787-4797. doi: 10.1182/blood-2009-07-230508
31. Dang CV (2012) MYC on the path to cancer. Cell 149:22-35. doi: 10.1016/j.cell.2012.03.003
32. Luscher B, Vervoorts J (2012) Regulation of gene transcription by the oncoprotein MYC. Gene 494:145-160. doi: 10.1016/j.gene.2011.12.027
33. Liao DJ, Dickson RB (2000) c-Myc in breast cancer. Endocr Relat Cancer 7:143-164
34. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L, Dimitrov K (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317-325. doi: 10.1038/nbt1385
35. Dimitroulakos J, Yeger H (1996) HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 2:326-333
36. Kodach LL, Bleuming SA, Peppelenbosch MP, Hommes DW, van den Brink GR, Hardwick JC (2007) The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 133:1272-1281. doi: 10.1053/j.gastro.2007.08.021
37. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30:1879-1887. doi: 10.1200/JCO.2011.38.2010
38. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW (2011) MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 71:2286-2297. doi: 10.1158/0008-5472.CAN-10-3367
39. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW (2007) Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110:2674-2684. doi: 10.1182/blood-2006-09- 048033